2021
DOI: 10.1182/blood-2021-145902
|View full text |Cite
|
Sign up to set email alerts
|

Trametinib for Refractory Chylous Effusions in Children with Noonan Syndrome

Abstract: BACKGROUND Noonan syndrome (NS) is one of several autosomal dominant multisystem disorders known as RASopathies. Common manifestations of NS include congenital heart defects and cardiomyopathy, lymphatic malformations, and predisposition to myeloproliferative disorders. Chylous fluid accumulation secondary to lymphatic malformations are seen in NS and are a major cause of morbidity and mortality often refractory to conventional medical management. There has been increasing interest in the use of… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
4
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 6 publications
(4 citation statements)
references
References 0 publications
0
4
0
Order By: Relevance
“…MEK inhibition with trametinib as a possible treatment has been described in few case reports of patients with Noonan syndrome and either hypertrophic cardiomyopathy or refractory life-threatening chylothorax. 4 , 5 , 6 , 12 , 13 The literature is sparse however and lacks guidelines regarding best treatment course. Doses between 0.01 to 0.027 mg/kg 4 , 5 , 12 have been reported, and all cases seem to continue on trametinib for a prolonged time and without a predetermined duration (Nakano et al .…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…MEK inhibition with trametinib as a possible treatment has been described in few case reports of patients with Noonan syndrome and either hypertrophic cardiomyopathy or refractory life-threatening chylothorax. 4 , 5 , 6 , 12 , 13 The literature is sparse however and lacks guidelines regarding best treatment course. Doses between 0.01 to 0.027 mg/kg 4 , 5 , 12 have been reported, and all cases seem to continue on trametinib for a prolonged time and without a predetermined duration (Nakano et al .…”
Section: Discussionmentioning
confidence: 99%
“…Very few cases have been published reporting successful treatment of patients with trametinib where all conventional treatments had failed. 5 , 6 We present a girl with Noonan’s syndrome, HCM, and refractory chylothorax who developed life-threatening chyle loss related complications. Lymphatic remodelling with complete resolution of chylothorax was achieved by MEK inhibition with trametinib.…”
Section: Timelinementioning
confidence: 99%
“…Patients who were considered underweight (BMI‐for‐age percentile ≤5%) or at risk for being underweight (BMI‐for‐age percentile 5–10%) demonstrated significant increases in weight‐for‐age percentile that placed 80% of them in a normal BMI class, a potential beneficial side effect for these patients 16 . This may be particularly advantageous for the subset of children with Noonan and Costello syndrome (conditions associated with short stature, feeding difficulties, and delayed growth) where patients have previously been noted to have improvement in their height and weight percentiles after initiation of a MEK inhibitor.…”
Section: Discussionmentioning
confidence: 99%
“…Due to thrombocytopenia and anemia, a bone marrow biopsy was performed, which showed hypocellularity without concern for dysplasia or cytogenetic abnormalities. She was started on trametinib for the chylothorax at 1 month of age based on studies showing response in patients with Noonan syndrome, 4,5 with improvement in respiratory symptoms, weaning respiratory support, and removal of chest tubes. She subsequently developed progressive cytopenia, thought to be a side effect of trametinib, so this was discontinued (see Table 1 for clinical course, counts, and bone marrow results).…”
Section: E T T E R T O T H E E D I T O R a Case Report Of Myelodyspla...mentioning
confidence: 99%